scholarly journals Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients

1988 ◽  
Vol 57 (6) ◽  
pp. 619-622 ◽  
Author(s):  
PG McKenna ◽  
KL O'Neill ◽  
WP Abram ◽  
BM Hannigan
Keyword(s):  
Breast Cancer ◽  
Thymidine Kinase ◽  
Cancer Patients ◽  
Mononuclear Leukocytes ◽  
Breast Cancer Patients

scholarly journals Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes

2020 ◽  
Vol 40 (4) ◽  
Author(s):  
Zhiwu Wang ◽  
Wei Zhang ◽  
Bingjie Huo ◽  
Liang Dong ◽  
Jing Zhang
Keyword(s):  
Breast Cancer ◽  
Thymidine Kinase ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Univariate Analysis ◽  
Clinical Parameters ◽  
Breast Cancer Patients ◽  
Thymidine Kinase 1 ◽  
Node Number ◽  
Significant Difference

Abstract In a retrospective study design, we explored the relationship between serum thymidine kinase 1 (TK1) concentration before radiotherapy and clinical parameters and evaluated the prognostic value of serum TK1 concentration before radiotherapy in breast cancer patients with type 2 diabetes mellitus. The present study finally consisted of 428 breast cancer patients with a mean age of 53.0 years. Compared with low TK1 group, the high TK1 group tended to have larger tumor size (P=0.011) and had more lymph node number (P=0.021). Significant differences were also observed in clinical stages I, II and III (P=0.000). There was no significant difference between TK1 and other clinical parameters. For disease-free survival (DFS), the univariate analysis indicated that the high TK1 increased the risk of poor prognosis (HR = 2.38, 95% CI: 1.64–4.23, P=0.000). The Kaplan–Meier curve indicated the high TK1 group was poorer than that in the low TK1 group (P=0.002). For the overall survival (OS), similar results were found that the high TK1 was related to poor OS (HR = 1.89, 95% CI: 1.34–3.67, P=0.000). The multivariate Cox regression indicated that the TK1 was still associated with DFS (HR = 1.83, 95% CI: 1.22–3.17, P=0.001) and OS (HR = 1.63, 95% CI: 1.19–2.08, P=0.006). The high pretreatment serum TK1 levels in breast cancer patients were associated with poor OS and DFS. TK1 could be a potential predictive factor in differential diagnosis of poor prognosis from all patients.

The Clinical Significance of Thymidine Kinase 1 Measurement in Serum of Breast Cancer Patients Using Anti-TK1 Antibody

2000 ◽  
Vol 15 (2) ◽  
pp. 139-146 ◽  
Author(s):  
Q. He ◽  
L. Zou ◽  
P.A. Zhang ◽  
J.X. Lui ◽  
S. Skog ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Healthy Volunteers ◽  
Thymidine Kinase ◽  
Cancer Patients ◽  
Polyclonal Antibodies ◽  
Benign Tumors ◽  
Breast Cancer Patients ◽  
Dot Blot ◽  
Significant Difference ◽  
Dot Blot Assay

The activity of total thymidine kinase in serum (S-TK) has been used as a tumor maker for decades. To date such activity has been determined using [125]I-iodo-deoxyuridine as a substrate. The aim of this study was to develop a new, antibody-based technique for the measurement of cytoplasmic thymidine kinase (TK1) in serum. Both mono- and polyclonal antibodies against S-TK1 were used in dot blot assay. S-TK1 was characterized by SDS and IEF techniques. Sixty-five breast cancer patients were studied, including 17 preoperative and 38 postoperative tumor-free patients and 10 patients with metastases to the lymph nodes (N1–2). They were compared to patients with benign tumors (n=21) and healthy volunteers (n=11). S-TK1 was low (0–1.0 pM) in healthy volunteers, while in preoperative patients the level was increased 6–110-fold. Significant differences were observed between preoperative patients and healthy volunteers (p=0.005), preoperative patients and patients with benign tumors (p<0.001), and preoperative patients and postoperative patients without metastases (p<0.001). No significant difference was observed between preoperative patients and postoperative patients with metastases (p=0.191). The S-TK activity in preoperative patients was also high in serum, but no decrease was observed following surgery. In conclusion, the anti-TK1 antibody could be a good marker for monitoring the response of breast cancer patients to therapy.

Sign in / Sign up

Export Citation Format

Share Document